CLINICAL COMPLIANCE 2010 - How to Set up Data Monitoring Committees (DMCs / DSMBs) and what is effect on the Drug Development Process - Clinical webinar By ComplianceOnline

Website http://complianceonline.com/ecommerce/control/trainingFocus/~product_id=701727?channel=ourglocal | Edit Freely

Category Clinical Webinar ,conference,event.

Deadline: December 10, 2010 | Date: December 10, 2010

Venue/Country: Palo Alto, U.S.A

Updated: 2010-12-03 15:52:28 (GMT+9)

Call For Papers - CFP

Data Monitoring Committees (DMCs, DSMBs) are increasingly seen as an integral part of multi centered trials. They are set-up by the sponsors of this research but impact every level of the process. You will learn how the key to their function is as an unblinded oversight group that is independent and has an absolute absence of any Conflicts of Interest. How the key is the handling of confidential information. You will see how safety monitoring is mandated throughout the regulations (21 CFR 312.50, 312.56, and 600.80 for drugs and biologics and 21 CFR 812.40 and 812.46 for devices) and depends on the nature of the test agent, the vulnerability of the study population, the length of the study, or the number of sites conducting the clinical study.

The FDA has increasingly recommended and sometimes mandated that a DMC be involved to advise the sponsor regarding subject safety. The "Stopping Rules" are an important element in a DMC function. Learn why the overriding reasons for a carefully selected (no Conflict of Interest) unblinded, independent, statistician controlled DMC is to promote and guarantee human subject safety as well as data integrity.

Note: Use This PromoCode( 108530 ) To Get 10% Discount valid till Dec 20th.